FDA D.I.S.C.O.: FDA approval of cabozantinib for hepatocellular carcinoma
FDA D.I.S.C.O.: FDA approval of cabozantinib for hepatocellular carcinoma FDA medical oncologists discuss the January 14, 2019, approval of cabozantin...
FDA Drug Information Soundcast in Clinical Oncology (D.I.S.C.O.)
Share:
Listens: 48
About
FDA Drug Safety Podcasts
FDA D.I.S.C.O.: Olaparib for gBRCAm HER2-negative metastatic breast cancer
FDA medical oncologists discuss the January 12, 2018, approval of olaparib, the first PARP inhibitor approved for the treatment of patients with metas...
FDA D.I.S.C.O.: Intro by Dr. Richard Pazdur
FDA D.I.S.C.O.: Intro by Dr. Richard Pazdur In our inaugural podcast, Dr. Richard Pazdur, director of the FDA Oncology Center of Excellence, talks wit...
FDA D.I.S.C.O.: Rucaparib in Ovarian Cancer
FDA D.I.S.C.O.: Rucaparib in Ovarian Cancer FDA medical oncologists discuss the agency’s December 2016 accelerated approval of rucaparib for treatment...
FDA D.I.S.C.O.: Niraparib in Ovarian Cancer Transcript
FDA medical oncologists discuss the agency’s March 2017 approval of niraparib for the maintenance treatment of patients with recurrent epithelial ovar...
FDA D.I.S.C.O.: Avelumab in Merkel Cell Carcinoma Transcript
FDA D.I.S.C.O.: Avelumab in Merkel Cell Carcinoma FDA medical oncologists discuss the agency’s March 23, 2017, approval of avelumab the treatment of p...
FDA D.I.S.C.O.: First Tissue/Site Agnostic Approval Transcript
The D.I.S.C.O. hosts discuss the agency’s first approval of a cancer treatment based on a common biomarker rather than the location in the body where ...
FDA D.I.S.C.O.: Two approvals for ALK-positive non-small cell lung cancer
FDA medical oncologists discuss the FDA approvals of brigatinib and ceritinib for ALK-positive non-small cell lung cancer.
FDA D.I.S.C.O.: L-glutamine for sickle cell disease
FDA D.I.S.C.O.: L-glutamine for sickle cell disease. FDA medical oncologists discuss the July 7, 2017, approval of l-glutamine to reduce the acute com...
FDA D.I.S.C.O.: Osimertinib for Non-Small Cell Lung Cancer
FDA D.I.S.C.O.: Osimertinib for Non-Small Cell Lung Cancer FDA medical oncologists discuss the approval of osimertinib for EGFR mutation-positive non-...